King Pharmaceuticals KG Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | ||
|---|---|---|---|---|---|
| $62.21M+153% | $24.63M-39.2% | $40.52M+20.4% | $33.67M+887% | ||
| $8.51M— | —— | —— | —— | ||
| $339.34M— | —— | —— | —— | ||
| $964.23M— | —— | —— | —— | ||
| $174.72M— | —— | —— | —— | ||
| $842.79M— | —— | —— | —— | ||
| 42.5M— | —— | —— | —— | ||
| -$6.23M— | —— | —— | —— | ||
| $121.44M-5.3% | $128.28M-10.8% | $143.77M-4.2% | $150.09M+3,451% | ||
| $964.23M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are King Pharmaceuticals's total assets?
- King Pharmaceuticals (KG) holds $964.2M in total assets.
- How much debt does King Pharmaceuticals have?
- King Pharmaceuticals carries $176.7M in total debt against $121.4M of shareholders' equity, a debt-to-equity ratio of 1.46.
- How much cash does King Pharmaceuticals have?
- King Pharmaceuticals holds $62.2M in cash and equivalents.
- Where does King Pharmaceuticals's balance sheet data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
